XML 18 R5.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Common stock
2023 Neurocrine Collaborative Agreement
Common stock
2023 Novartis Collaboration Agreement
Common stock
Additional paid-in capital
2023 Neurocrine Collaborative Agreement
Additional paid-in capital
2023 Novartis Collaboration Agreement
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
2023 Neurocrine Collaborative Agreement
2023 Novartis Collaboration Agreement
Total
Stockholders' Equity, Beginning Balance at Dec. 31, 2022     $ 38     $ 452,713 $ (219) $ (393,512)     $ 59,020
Shares, Outstanding, Beginning Balance at Dec. 31, 2022     38,613,891                
Exercises of vested stock options           185         185
Exercises of vested stock options (in shares)     51,993                
Vesting of restricted stock units (in shares)     374,417                
Issuance of common stock $ 5     $ 31,116         $ 31,121    
Issuance of common stock (in shares) 4,395,588                    
Stock based compensation expense           2,504         2,504
Unrealized gain (loss) on available-for-sale securities, net of tax             87       87
Net income (loss)               124,044     124,044
Stockholders' Equity, Ending Balance at Mar. 31, 2023     $ 43     486,518 (132) (269,468)     216,961
Shares, Outstanding, Ending Balance at Mar. 31, 2023     43,435,889                
Stockholders' Equity, Beginning Balance at Dec. 31, 2023     $ 44     497,506 (48) (261,182)     236,320
Shares, Outstanding, Beginning Balance at Dec. 31, 2023     44,038,333                
Exercises of vested stock options           78         $ 78
Exercises of vested stock options (in shares)     32,500               32,500
Vesting of restricted stock units (in shares)     324,520                
Issuance of common stock   $ 2     $ 19,303         $ 19,305  
Issuance of common stock (in shares)   2,145,002                  
Issuance of common stock and pre-funded warrants in connection with underwritten public offering     $ 8     93,465         $ 93,473
Issuance of common stock and pre-funded warrants in connection with underwritten public offering (in shares )     7,777,778                
Stock based compensation expense           3,498         3,498
Unrealized gain (loss) on available-for-sale securities, net of tax             (458)       (458)
Net income (loss)               (11,330)     (11,330)
Stockholders' Equity, Ending Balance at Mar. 31, 2024     $ 54     $ 613,850 $ (506) $ (272,512)     $ 340,886
Shares, Outstanding, Ending Balance at Mar. 31, 2024     54,318,133